Axial Spondyloarthritis (axSpA) Epidemiology Forecast 2025-2034

Axial spondyloarthritis (axSpA) epidemiology forecast suggests that 0.1% to 1% of the general population is affected by ankylosing spondylitis (a type of axial spondyloarthritis), with the male-to-female ratio reported to be around 3:1. Studies show a strong genetic predisposition exists between the disease and the HLA-B27 genetic marker. According to a 2018 review article, the percentage of people in the United States who have axial spondyloarthritis (axSpA) (0.9% to 1.4%) is higher than the percentage of people who have been diagnosed with it (0.2% to 0.7%).

Axial Spondyloarthritis (axSpA) Epidemiology Forecast Report Coverage

The “Axial Spondyloarthritis (axSpA) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of axial spondyloarthritis (axSpA). It projects the future incidence and prevalence rates of axial spondyloarthritis (axSpA) cases across various populations. The study covers age, gender, and type as major determinants of the axial spondyloarthritis (axSpA) population. The report highlights patterns in the prevalence of axial spondyloarthritis (axSpA) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on axial spondyloarthritis (axSpA) epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Axial Spondyloarthritis (axSpA) Understanding: Disease Overview

Axial spondyloarthritis (axSpA) refers to an inflammatory arthritis that primarily affects the spine and sacroiliac joints. The condition is characterized by pain, stiffness, and inflammation, particularly in the lower back and hips. It is observed that symptoms usually worsen after periods of rest. Axial spondyloarthritis (axSpA) can gradually lead to the fusion of the spine, which limits movement.

AxSpA is a broader category of disease that includes two main types: radiographic axSpA (ankylosing spondylitis or AS) and non-radiographic axSpA. Most axial spondyloarthritis (axSpA) patients have a gene called HLA-B27. In addition to spine and joint pain, axSpA can also affect other parts of the body, including the eyes (uveitis) and other joints outside of the spine.

Axial Spondyloarthritis (axSpA) Epidemiology Perspective

The axial spondyloarthritis (axSpA) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for axial spondyloarthritis (axSpA) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for axial spondyloarthritis (axSpA) and their trends. The axial spondyloarthritis (axSpA) detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• In the United Kingdom, about 1 in 200 of the adult population is affected by axial spondyloarthritis (axSpA), as per the report compiled by the National Axial Spondyloarthritis Society.
• The prevalence of axial spondyloarthritis (axSpA) is estimated to range between 0.1% and 1.4% worldwide, with geographic differences attributed primarily to the prevalence of HLA-B27 antigen, according to a research article published in the Best Practice & Research Clinical Rheumatology (2018).
• As per a 2018 review article, the percentage of people in the United States who have axial spondyloarthritis (0.9% to 1.4%) is higher than the percentage of people who have been diagnosed with it (0.2% to 0.7%).
• A significant challenge in treating axial spondyloarthritis (axSpA) is the delay in diagnosis, which often ranges from 5 to 14 years after the onset of symptoms.

Age-Based Axial Spondyloarthritis (axSpA) Epidemiology Insights

Axial spondyloarthritis (axSpA) typically begins in the second or third decade of life, usually affecting individuals in their 20s or 30s. The onset of the condition after the age of 50 is considered uncommon. Research has shown that the majority of people with axial spondyloarthritis (axSpA) develop symptoms, such as back pain, before the age of 45.

Gender-Based Axial Spondyloarthritis (axSpA) Epidemiology Insights

Ankylosing spondylitis (AS) occurs in 0.1% to 1% of the general population, with a male-to-female ratio of approximately 3:1, according to Malakar, Alokjyoti, et al. (2020). On the other hand, the male-to-female ratio in non-radiographic axial spondyloarthritis (nr-axSpA) is closer to 1:1, as per the Spondylitis Association of America.

Country-wise Axial Spondyloarthritis (axSpA) Epidemiology Segment

The axial spondyloarthritis (axSpA) epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of axial spondyloarthritis (axSpA) varies between countries, owing to differences in factors such as genetic predisposition (the presence of the HLA-B27 gene), environmental influences, access to healthcare, diagnostic practices, and sociodemographic factors (age, gender, and ethnicity), among others. In the United States, an estimated 1.6 million people have non-radiographic axial spondyloarthritis (nr-axSpA) and 3.2 million people have ankylosing spondylitis, as per the Spondylitis Association of America.

Axial Spondyloarthritis (axSpA): Treatment Overview

The treatment approach for axial spondyloarthritis (axSpA) typically involves a combination of medication, physical therapy, and lifestyle changes. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, are the first line of treatment for axSpA. These axial spondyloarthritis (axSpA) therapeutics help reduce pain and inflammation.

In moderate to severe axial spondyloarthritis (axSpA) cases, biologic drugs like TNF inhibitors (tumor necrosis factor inhibitors), including infliximab, etanercept, and adalimumab, may be recommended. IL-17 inhibitors (interleukin-17 inhibitors), such as secukinumab and ixekizumab, target IL-17, which is another treatment option to help reduce symptoms and prevent joint damage.

Key Questions Answered

• What are the key findings of axial spondyloarthritis (axSpA) epidemiology in the 8 major markets?
• What will be the total number of patients with axial spondyloarthritis (axSpA) across the 8 major markets during the forecast period?
• What was the country-wise axial spondyloarthritis (axSpA) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of axial spondyloarthritis (axSpA) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of axial spondyloarthritis (axSpA) during the forecast period of 2025-2034?
• What are the currently available treatments in the axial spondyloarthritis (axSpA) market?
• What are the disease risks, signs, symptoms, and unmet needs of axial spondyloarthritis (axSpA)?

Scope of the Axial Spondyloarthritis (axSpA) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of axial spondyloarthritis (axSpA) based on several factors.
• Axial Spondyloarthritis (axSpA) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The axial spondyloarthritis (axSpA) report helps to identify the patient population and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.